





HOME » THE NUREMBERG CODE AND ITS IMPACT ON CLINICAL RESEARCH

The Nuremberg Code and its impact on clinical research

APRIL 9, 2019 BY [MASSDEVICE](#)



The Nuremberg Code is one of the most influential documents in the history of clinical research.



Natalie Jarmusik, Clinical Research Associate, IMARC Research

The Nuremberg Code is one of the most influential documents in the history of clinical research.

Created more than 70 years ago following the notorious World War II experiments, this written document established 10 ethical principles for protecting human subjects.

We'll take a closer look at its origins, its guidelines and its enduring impact.

What Is the Nuremberg Code?

When **World War II** ended in 1945, the victorious Allied powers enacted the International Military Tribunal on November 19th, 1945. As part of the Tribunal, a series of trials were held against major war criminals and Nazi sympathizers holding leadership positions in political, military, and economic areas. The first trial conducted under the Nuremberg Military Tribunals in 1947 became known as The Doctors' Trial, in which 23 physicians from the German Nazi Party were tried for crimes against humanity for the atrocious experiments they carried out on unwilling prisoners of war. Many of the grotesque medical experiments took place at the Auschwitz concentration camp, where Jewish prisoners were tattooed with dehumanizing numbers onto their arms; numbers that would later be used to identify their bodies after death.

The Doctors' Trial is officially titled "The United States of America v. Karl Brandt, et al.," and it was conducted at the Palace of Justice in Nuremberg, Bavaria, Germany. The trial was conducted here because this was one of the few largely undamaged buildings that remained intact from extensive Allied bombing during the war. It is also said to have been symbolically chosen because it was the ceremonial birthplace of the Nazi Party. Of the 23 defendants, 16 were found guilty, of which seven received death sentences and nine received prison sentences ranging from 10 years to life imprisonment. The other 7 defendants were acquitted.


The verdict also resulted in the creation of the **Nuremberg Code**, a set of ten ethical principles for human experimentation.

What Are The Nuremberg Code's Ethical Guidelines For Research?

The Nuremberg Code aimed to protect human subjects from enduring the kind of cruelty and exploitation the prisoners endured at concentration camps. The 10 elements of the code are:

1. Voluntary consent is essential
2. The results of any experiment must be for the greater good of society
3. Human experiments should be based on previous animal experimentation
4. Experiments should be conducted by avoiding physical/mental suffering and injury
5. No experiments should be conducted if it is believed to cause death/disability
6. The risks should never exceed the benefits
7. Adequate facilities should be used to protect subjects
8. Experiments should be conducted only by qualified scientists
9. Subjects should be able to end their participation at any time
10. The scientist in charge must be prepared to terminate the experiment when injury, disability, or death is likely to occur

Want to learn more about the history of clinical research? Take a minute to **watch the video** and explore our **History of Clinical Research timeline** for more detail.



The Significance Of The Nuremberg Code

The Nuremberg Code is one of several foundational documents that influenced the principles of Good Clinical Practice (GCP).

Good Clinical Practice is an attitude of excellence in research that provides a standard for study design, implementation, conduct and analysis. More than a single document, it is a compilation of many thoughts, ideas and lessons learned throughout the history of clinical research worldwide.

Several other documents further expanded upon the principles outlined in the Nuremberg Code, including the Declaration of Helsinki, the Belmont Report and the Common Rule.

Although there has been updated guidance to Good Clinical Practice to reflect new trends and technologies, such as electronic signatures, these basic principles remain the same. The goal has always been—and always will be—to conduct ethical clinical trials and protect human subjects.

The opinions expressed in this post are the author's only and do not necessarily reflect those of MedicalDesignandOutsourcing.com or its employees.

FILED UNDER: [BLOG, CLINICAL TRIALS](#)
TAGGED WITH: [IMARC](#)

Powered by **TREND MD**


IN CASE YOU MISSED IT

- › [Launching your med device: A strategy & execution cross-functional guide](#)
- › [FDA allows booster dose Pfizer-BioNTech COVID-19 vaccine in children 5 to 11](#)
- › [FDA clears DePuy Synthes' Inhanse for total shoulder arthroplasty](#)
- › [Henry Schein hires former Medline veteran to drive 'One Distribution' push](#)
- › [FDA authorizes Labcorp's non-prescription COVID-19 test that also detects flu, RSV](#)
- › [Massachusetts is competing for ARPA-H biomedical research center](#)
- › [Vivasure raises \\$23M initial Series D tranche; could reach up to \\$54M](#)
- › [Exactech announces breakthrough nod for JointMedica's hip resurfacing system](#)
- › [Accuray names Sandeep Chalke as chief commercial officer](#)
- › [Labcorp launches at-home collection device for diabetes risk testing](#)
- › [Medtronic's renal denervation system demonstrates better blood pressure control, time in range](#)
- › [iRhythm stays silent on federal grand jury subpoenas](#)
- › [Texas power grid struggles a year after cold stopped semiconductor plants](#)
- › [The road to a robot: Medtronic's development process for its Hugo RAS system](#)
- › [How Dexcom's portfolio goes beyond highly-anticipated next-gen G7](#)
- › [Zimmer Biomet appoints new chief accounting officer](#)
- › [Cook Medical makes next-gen in vitro fertilization incubator available in U.S., Canada](#)


FROM MEDICAL DESIGN & OUTSOURCING

- › [Instron releases TrendTracker data analysis workflow platform](#)
Instron announced that it released the TrendTracker module in Bluehill Central for accelerating data analysis workflows. Norwood, Massachusetts-based Instron designed TrendTracker with an intuitive interface to improve the data analysis workflow of single or multi-location materials testing laboratories. According to a news release, the platform features quick searching and the ability to display and analyze... [.]
- › [Henry Schein hires former Medline veteran to drive 'One Distribution' push](#)
Henry Schein (Nasdaq:HSIC) today named Dirk Benson as VP and chief commercial officer of the medical device manufacturer and distributor's North America Distribution Group (NADG). Melville, New York-based Henry Schein is the world's largest provider of health care supplies and services for office-based dental and medical practitioners, and NADG is the company's largest business group. The... [.]
- › [The road to a robot: Medtronic's development process for its Hugo RAS system](#)
Elephants are the perfect analogy for surgical robotics. Medtronic (NYSE:MDT) VP of Marketing for Surgical Robotics Mike Stow says. Speaking on the "Road to a robot: Designing technology to address unmet needs & barriers" panel at DeviceTalks Boston last week, Stow explained that elephants are big, taking up a lot of space and that they eat a lot, making... [.]
- › [iRhythm stays silent on federal grand jury subpoenas](#)
More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker's initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a... [.]
- › [How Dexcom's portfolio goes beyond highly-anticipated next-gen G7](#)
A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company's CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association's Scientific Sessions next month. The company also presented... [.]
- › [Texas power grid struggles in heat one year after record cold stopped semiconductor plants](#)
A heatwave in Texas took at least six power plants offline Friday, with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semiconductor shortage that is still throttling medical device production. There's no indication... [.]
- › [How Stryker includes users for product design in the digital age](#)
Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan-based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker... [.]
- › [DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event](#)
DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event. The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with... [.]
- › [Steris rises on Street-beating Q4, sets fiscal 2023 guidance](#)
Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of \$52.3 million, or 52¢ per share, on sales of \$1.2 billion for the three months... [.]
- › [Lucira Health asks FDA for EUA on molecular at-home COVID/flu test](#)
Lucira Health (Nasdaq: LHDx) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California-based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a... [.]
- › [Device commercialization platform AcuityMD raises \\$31M Series A to fund R&D engineer hiring](#)
AcuityMD said today it has raised \$31 million in Series A funding for its medical device commercialization platform. "With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year," AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. "We'll... [.]

Search this website



DEVICETALKS WEEKLY



May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang


[See More >](#)

MEDTECH 100 INDEX


MEDTECH 100
Market Summary > Current Price
\$83.02
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
[CLICK FOR COMPANY DETAILS >>](#)

Need Medtech news in a minute? We Deliver!


MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.



Full Product Lifecycle


Highly engineered
Implantables &
Bioabsorbables,
Surgical Tools
& Instruments, and
Drug Discovery &
Delivery Medical
Devices & Assemblies.

DESIGN, DEVELOPMENT, & RAPID PROTOTYPING
RAMP-UP, LAUNCH, & COMMERCIAL-SCALE MFG.
ASSEMBLY & FINISHED GOODS PACKAGING



MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing • Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

DEVICE TALKS WEBINARS, PODCASTS, & DISCUSSIONS

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us